Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2003

View Archived Issues

RDP-58 safe and effective in ulcerative colitis

Monoclonal antibody specific for a T-cell integrin effective in ulcerative colitis

Effective treatment of pouchitis reported with ISIS-2302 enema

Pintex Pharmaceuticals claims Pin1 inhibitors and their use in cancer therapy

New MMP-13 inhibitors described in patent owned by Pfizer company

Several series of HDAC inhibitors described by Janssen

Novel CRH analogues for use in melanoma therapy designed at the U. of California

Signal patent describes novel ER modulators for osteoporosis, cancer, etc.

Novartis presents new DPP-IV inhibitors in a recent patent

Sodium/glucose cotransporter as a target for the treatment of diabetes

JNK pathway as a target for diabetes

Allergan to acquire Oculex

SAHA receives orphan drug status

SBIR grant supports anthrax antibody development efforts at Avanir

Phase I/II study of BSYX-L210 meets endpoints

Enrollment completed in phase II study of GPI-1485 for Parkinson's disease

Amgen selects Tularik compounds for optimization under collaboration

MLN-1202 enters phase II trial for rheumatoid arthritis

Anti-VE-cadherin antibody blocks folliculogenesis and corpus luteum formation

Potent, selective D3 receptor antagonist may have utility as antipsychotic and in drug addiction

Antimetastatic activity of Ono-4817 in mice bearing head and neck cancer

Good efficacy and safety profile for CDP-870 in Crohn's disease

Intravaginal WHI-07 safe in pregnant rabbits and fetuses following short-term administration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...